Conference abstract · 31 Aug 2015
Conference abstractPublished 15 Apr 2014
SAP-profiling in biomarker research
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
O ne of the main features of MS based quantification is clinical application used to identify biomarkers associated with diseases. Despite early expectations, proteomics failed to discover the expression biomarkers, withstanding the validation on large cohorts. Putative escape was enlightened by proteoformics, the offspring of proteomics for studying the variety of protein species, called proteoforms and arised as a consequence of single amino acid change, alternative splicing, post- translational modifications, and other yet unexplored molecular events. The phenomenon of SAPs was extensively studied by bottom-up shotgun mass-spectrometry. The new step is to match the MS/MS spectra against the somatic mutations, which can be expected from non-synonymic SNPs of cancer genome. Development of SAP-based digital biomarkers requires a number of clinically-relevant experiments matched against the cancer exomes deciphered by genome sequencing. The pipeline for investigation the information about cancer-associated SAP-based biomarkers is following. The cancer genomes upcoming from the large-scale COSMIC database are filtered to derive the nsSNPs, which can be additionally ranked for their influence onto the protein structure or functional significance. Selected nsSNPs are in silico translated into the protein sequence database. The database is searched towards the MS/MS spectra repositories, either general ones, like PRIDE, or preferably those, convicted to cancer tissue or cell lines. The MS/MS datasets are matched to the peptide?s mutations expected from the cancer genome, withdrawing the unaware cases of modifications while simple preparation. The remaining SAP-containing peptides are investigated for their occurrence in the control samples, and discarded in case of match. The rest has to be validated using the SRM targeted approach, which includes the synthesis of stable isotope standard (SIS) peptides, assay development and optimization. The additional verification has to be performed by PCR to confirm the corresponding mutation at the genome level. Cancer driver genes APC, TP53 и KRAS are affected in 42-71% of cases. However, each individual nsSNP is rarely observed. It means that each tumor accumulates a unique set of spontaneous mutations. There are many mutations to break the proto-oncogene or tumor suppressor; however, the mutation can occur in different sites along the gene. That property of the cancer tumor represents bad news for biomarkers which may reach the 100% specificity, but at the 9% sensitivity, as only 9% of tumors carry the particular mutation. We conclude that despite the technical level is ready to deliver information about proteoform-based biomarkers, still further increase in sensitivity and selectivity is required to validate the concept. The effort can be undertaken in frames of the Chromosome-centric Human Proteome Project, to open up a new format of diagnostics for clinical proteomics.
Ask about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Conference abstract · 15 Apr 2014
Proteomics for cancer biomarkers: From MALDI-TOF profiling to targeted proteogenomics
Conference abstract · 15 Apr 2014
Blood gene expression profiling to identify potential new biomarkers for ischemic stroke etiological classification
Conference abstract · 15 Jul 2013
Quantitative immunofluoresence profiling of therapy-relevant protein biomarkers for stratification of breast cancer patients
Conference abstract · 2 Jul 2012
Towards cancer biomarker discovery via proteomic and metabolomic profiling of clinical specimens
More from this journal
The newest in Journal of Molecular Biomarkers & Diagnosis.
Brief report · 29 Dec 2025
Biomarker Discovery To Clinical Translation: A Holistic Approach
Commentary · 29 Dec 2025
Molecular Diagnostics: Revolutionizing Precision Healthcare
Commentary · 29 Dec 2025
Genomic Biomarkers Revolutionizing Disease Diagnosis and Medicine
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Molecular Biomarkers & Diagnosis
- SubjectGenetics & Molecular Biology
- SubjectPathology & Lab Medicine
- BylineArticles whose byline prints “Andrey Lisitsa”
- BylineArticles whose byline prints “Olga Kiseleva”
- BylineArticles whose byline prints “Sergei Moshkovskii”
- BylineArticles whose byline prints “Alexander Archakov”

